Bank of America’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Bank of America’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-28,402	Closed	-$115K	–	8369
2023 Q4	$115K	Buy	28,402 +10,987	+63%	+$33.5K	﹤0.01%	6323
2023 Q3	$46.8K	Buy	17,415 +13,413	+335%	+$52.6K	﹤0.01%	6519
2023 Q2	$37.3K	Sell	4,002 -175,200	-98%	-$1.73M	﹤0.01%	6548
2023 Q1	$1.59M	Buy	179,202 +164,582	+1,126%	+$1.62M	﹤0.01%	4544
2022 Q4	$72.8K	Buy	14,620 +8,725	+148%	+$51.1K	﹤0.01%	6354
2022 Q3	$35K	Sell	5,895 -499	-8%	-$3.53K	﹤0.01%	6823
2022 Q2	$35K	Buy	6,394 +1,320	+26%	+$10.9K	﹤0.01%	6990
2022 Q1	$59K	Sell	5,074 -2,832	-36%	-$30.3K	﹤0.01%	7109
2021 Q4	$100K	Buy	+7,906	New	+$119K	﹤0.01%	6883

Bank of America's THRX Position: Q1 2024 in Review

Bank of America sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 28,402 shares — an estimated $115K sold.

Bank of America first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $1.59M in Q1 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

Bank of America reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Bank of America sold 28,402 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $115K.
Bank of America first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Bank of America's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $1.59M in Q1 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Bank of America's 13F filing for Q1 2024, filed 15 May 2024.